{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-040793","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2021-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.092720+00:00","generated_at":"2026-06-29T22:29:56.199906+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fate Therapeutics reports Q2 2021 results; first patient dosed with FT819 iPSC CAR T-cell therapy","bullets":["Q2 2021 revenue $13.4M from collaborations; R&D expenses $48.0M; cash & investments $845.1M.","First patient treated in Phase 1 trial of FT819, first-ever iPSC-derived CAR T-cell therapy, for ALL.","FT516 interim data at ASCO: 8/11 patients (73%) objective response, 6 complete responses in B-cell lymphoma.","FT538 Phase 1 in AML: 2 patients evaluable, 1 achieved CRi; dose escalation ongoing.","Appointed Dr. Mark Plavsic as Chief Technical Officer and Dr. Yuan Xu to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-040793","json":"https://secwatch.observer/filing/0001564590-21-040793.json","markdown":"https://secwatch.observer/filing/0001564590-21-040793.md","text":"https://secwatch.observer/filing/0001564590-21-040793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000156459021040793/0001564590-21-040793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000156459021040793/fate-8k_20210804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:29:56.199906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}